CTC
CORT icon

Central Trust Company’s Corcept Therapeutics CORT Stock Holding History

Central Trust Company’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$121 – 1596
2026
Q1 		$121 Hold
3
– – ﹤0.01% 1557
2025
Q4 		$105 Buy
+3
New +$236 ﹤0.01% 1531
2019
Q1 		– Sell
-623
Closed -$8K – 1101
2018
Q4 		$8K Sell
623
-90
-13% -$1.19K ﹤0.01% 933
2018
Q3 		$10K Buy
713
+110
+18% +$1.54K ﹤0.01% 1002
2018
Q2 		$9K Buy
603
+70
+13% +$1.22K ﹤0.01% 1010
2018
Q1 		$9K Buy
+533
New +$9.88K ﹤0.01% 999

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Central Trust Company's CORT Position: Q2 2026 in Review

Central Trust Company sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 3 shares — an estimated $121 sold.

Central Trust Company first reported a position in CORT in Q1 2018 and held it in 6 quarters. The position peaked at $10K in Q3 2018. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Central Trust Company reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Central Trust Company sold 3 Corcept Therapeutics shares in Q2 2026, an estimated $121.
  • Central Trust Company first reported a position in Corcept Therapeutics in Q1 2018 and held it in 6 quarters.
  • Central Trust Company's Corcept Therapeutics position peaked at $10K in Q3 2018.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.